A Randomized, Double-blind, Placebo-controlled Ascending Dose Study to Evaluate the Effect of APL180 on Endothelial Function in Patients With Familial Hypercholesterolemia
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs APL 180 (Primary)
- Indications Hyperlipoproteinaemia type II
- Focus Pharmacodynamics
- Sponsors Novartis Pharma
- 04 Nov 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 27 Sep 2008 New trial record.